Methylcis-9,cis-12,cis-15-octadecatrienoate-15,16-d 2 was obtained from Wittig coupling of methyl 12-oxo-cis-9-dodecenoate,18, and 3,4-dideutero-cis-3-hexenyltriphenylphosphonium bromide,16. Compound18 was obtained by periodic acid oxidation of methyl 12,13-dihydroxy-cis-9-octadecenoate,17, obtained fromVernonia oil. Compound18 also was synthesized from methyl oleate as the starting material. The deuterated fragment,16, was prepared from 3-hexynol and using Lindlar's catalyst and deuterium gas to introduce the deuterium atoms.Methylcis-9,cis-12,cis-15-octadecatrienoate-6,6,7,7-d 4 was prepared by Wittig coupling of 3,6-nonadienyltriphenylphosphonium iodide,5, with methyl 9-oxononanoate-6,6,7,7-d 4,11. Deuterium atoms were introduced during the synthesis of11 from 3-butynol and 5-bromopentanoic acid with deuterium gas in the presence of [Ph3P]3-RhCl. For the preparation of5, the 3,6-nonadiynol intermediate was reduced to 3,6-nonadienol with P-2 Nickel and hydrogen.The final products were separated from isomers formed during the synthetic sequences by silver resin chromatography.
No takes yet. Share an insight, caveat, or question.
Henry Rakoff (1988) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: